20.10
price up icon0.70%   0.14
after-market アフターアワーズ: 20.10
loading
前日終値:
$19.96
開ける:
$20.02
24時間の取引高:
1.59M
Relative Volume:
1.07
時価総額:
$1.78B
収益:
$172.60M
当期純損益:
$-285.42M
株価収益率:
-6.0977
EPS:
-3.2963
ネットキャッシュフロー:
$-323.17M
1週間 パフォーマンス:
-4.78%
1か月 パフォーマンス:
-20.08%
6か月 パフォーマンス:
+33.11%
1年 パフォーマンス:
+48.12%
1日の値動き範囲:
Value
$19.45
$20.15
1週間の範囲:
Value
$19.00
$21.55
52週間の値動き範囲:
Value
$8.58
$25.59

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Name
名前
Syndax Pharmaceuticals Inc
Name
セクター
Healthcare (1106)
Name
電話
781-419-1400
Name
住所
730 THIRD AVENUE, NEW YORK, MA
Name
職員
298
Name
Twitter
@syndax
Name
次回の収益日
2026-04-30
Name
最新のSEC提出書
Name
SNDX's Discussions on Twitter

Compare SNDX vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
SNDX icon
SNDX
Syndax Pharmaceuticals Inc
20.10 1.77B 172.60M -285.42M -323.17M -3.2963
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
424.36 109.34B 12.32B 4.34B 3.19B 16.86
REGN icon
REGN
Regeneron Pharmaceuticals Inc
702.27 74.35B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
794.70 50.44B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
301.11 39.78B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
297.49 33.02B 5.36B 287.73M 924.18M 2.5229

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-10-16 再開されました H.C. Wainwright Buy
2025-09-10 再開されました Stifel Buy
2025-09-04 再開されました Guggenheim Buy
2025-08-05 繰り返されました BTIG Research Buy
2025-07-10 開始されました Goldman Buy
2024-10-24 開始されました UBS Buy
2024-06-28 開始されました Jefferies Buy
2024-01-31 ダウングレード Scotiabank Sector Outperform → Sector Perform
2023-12-22 開始されました Mizuho Buy
2023-10-25 開始されました BofA Securities Buy
2023-10-11 開始されました Goldman Buy
2023-07-27 開始されました Scotiabank Sector Outperform
2023-07-11 開始されました Guggenheim Buy
2023-04-17 再開されました BTIG Research Buy
2023-01-31 開始されました Stifel Buy
2023-01-03 開始されました JP Morgan Overweight
2022-07-28 再開されました B. Riley Securities Buy
2022-04-11 開始されました H.C. Wainwright Buy
2022-02-15 開始されました Goldman Buy
2021-06-04 再開されました Robert W. Baird Outperform
2021-05-25 開始されました Citigroup Buy
2021-02-18 開始されました B. Riley Securities Buy
2020-12-03 開始されました Stifel Buy
2020-05-22 アップグレード Citigroup Neutral → Buy
2020-05-22 ダウングレード H.C. Wainwright Buy → Neutral
2020-05-18 ダウングレード Citigroup Buy → Neutral
2020-05-11 繰り返されました H.C. Wainwright Buy
2020-03-04 開始されました Barclays Overweight
2020-01-13 繰り返されました H.C. Wainwright Buy
2019-03-08 繰り返されました H.C. Wainwright Buy
2019-01-04 開始されました Robert W. Baird Outperform
2018-01-05 開始されました B. Riley FBR, Inc. Buy
2017-03-16 開始されました FBR & Co. Outperform
2017-03-02 開始されました Instinet Buy
2016-10-07 開始されました Guggenheim Buy
2016-03-28 開始されました Citigroup Buy
2016-03-28 開始されました JMP Securities Mkt Outperform
2016-03-28 開始されました Morgan Stanley Overweight
すべてを表示

Syndax Pharmaceuticals Inc (SNDX) 最新ニュース

pulisher
May 05, 2026

Syndax Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:SNDX) 2026-05-05 - Seeking Alpha

May 05, 2026
pulisher
May 05, 2026

HC Wainwright Has Optimistic Outlook of SNDX Q2 Earnings - MarketBeat

May 05, 2026
pulisher
May 05, 2026

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - simplywall.st

May 05, 2026
pulisher
May 04, 2026

(SNDX) Risk Channels and Responsive Allocation - Stock Traders Daily

May 04, 2026
pulisher
May 04, 2026

Biotech Momentum Builds As Syndax Pharmaceuticals Draws Market Attention - Kalkine Media

May 04, 2026
pulisher
May 04, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% Following Analyst Upgrade - MarketBeat

May 04, 2026
pulisher
May 04, 2026

Stifel raises Syndax Pharmaceuticals stock price target on therapy outlook By Investing.com - Investing.com Canada

May 04, 2026
pulisher
May 04, 2026

Stifel raises Syndax Pharmaceuticals stock price target on therapy outlook - Investing.com

May 04, 2026
pulisher
May 04, 2026

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Released Its First-Quarter Earnings: Here's What Analysts Think - 富途牛牛

May 04, 2026
pulisher
May 04, 2026

HC Wainwright Has Optimistic Outlook of SNDX FY2030 Earnings - MarketBeat

May 04, 2026
pulisher
May 03, 2026

MSN Money - MSN

May 03, 2026
pulisher
May 03, 2026

Syndax Pharmaceuticals (SNDX) Narrows Q1 Loss To US$42.7 Million Challenging Bearish Narratives - Sahm

May 03, 2026
pulisher
May 02, 2026

Net current asset value per share of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView

May 02, 2026
pulisher
May 02, 2026

Syndax Pharmaceuticals Q1 Loss Narrows, Revenue Rises - Moomoo

May 02, 2026
pulisher
May 02, 2026

Syndax Pharmaceuticals Reports Over $100 Million in Q1 Combined Sales - HarianBasis.co

May 02, 2026
pulisher
May 02, 2026

Jefferies Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $37 - Moomoo

May 02, 2026
pulisher
May 01, 2026

Syndax Pharmaceuticals 1Q Loss $42.7M >SNDX - Moomoo

May 01, 2026
pulisher
May 01, 2026

Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain TractionWhat’s Really Shifting? - Yahoo Finance

May 01, 2026
pulisher
May 01, 2026

Syndax Pharmaceuticals Inc ($SNDX) CEO 2025 Pay Revealed - Quiver Quantitative

May 01, 2026
pulisher
May 01, 2026

Stifel raises Syndax Pharmaceuticals stock price target on therapy trajectory By Investing.com - Investing.com Canada

May 01, 2026
pulisher
May 01, 2026

Jefferies cuts Syndax Pharmaceuticals price target on transplant impact By Investing.com - Investing.com Canada

May 01, 2026
pulisher
May 01, 2026

SNDX Maintained by Barclays -- Price Target Raised to $37 - GuruFocus

May 01, 2026
pulisher
May 01, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 7.1%Time to Sell? - MarketBeat

May 01, 2026
pulisher
May 01, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $37.00 - MarketBeat

May 01, 2026
pulisher
May 01, 2026

Syndax Pharmaceuticals stock price target raised to $29 by BofA - Investing.com Australia

May 01, 2026
pulisher
May 01, 2026

Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highligh - GuruFocus

May 01, 2026
pulisher
May 01, 2026

SNDX SWOT Analysis: Financial Resilience Amidst Clinical Development Challenges Revealed in 10-Q Filing - GuruFocus

May 01, 2026
pulisher
May 01, 2026

Earnings Call Summary | Syndax Pharmaceuticals(SNDX.US) Q1 2026 Earnings Conference - Moomoo

May 01, 2026
pulisher
May 01, 2026

Syndax Pharmaceuticals (SNDX) Reports Strong Q1 2026 Earnings an - GuruFocus

May 01, 2026
pulisher
Apr 30, 2026

Syndax Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat

Apr 30, 2026
pulisher
Apr 30, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Quarterly Earnings Results - MarketBeat

Apr 30, 2026
pulisher
Apr 30, 2026

SNDX Sees Strong Demand Despite Q1 Revenue Miss - GuruFocus

Apr 30, 2026
pulisher
Apr 30, 2026

How Should Investors Value Syndax Pharmaceuticals (SNDX) After Q - GuruFocus

Apr 30, 2026
pulisher
Apr 30, 2026

Earnings call transcript: Syndax Pharmaceuticals beats Q1 2026 EPS expectations - Investing.com

Apr 30, 2026
pulisher
Apr 30, 2026

Earnings Flash (SNDX) Syndax Pharmaceuticals Posts Q1 Loss $0.48, vs. FactSet Est of $0.61 Loss - marketscreener.com

Apr 30, 2026
pulisher
Apr 30, 2026

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Apr 30, 2026
pulisher
Apr 30, 2026

Syndax (NASDAQ: SNDX) details 2026 virtual meeting, director votes and 7.2M-share plan - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

Q1 2026 Syndax Pharmaceuticals Inc Earnings Call Transcript - GuruFocus

Apr 30, 2026
pulisher
Apr 30, 2026

SNDX: Revenue up 224% to $64.9M; net loss halved; strong growth in Revuforj and Niktimvo sales - TradingView

Apr 30, 2026
pulisher
Apr 30, 2026

Syndax: Q1 Earnings Snapshot - KVUE

Apr 30, 2026
pulisher
Apr 30, 2026

Syndax Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times

Apr 30, 2026
pulisher
Apr 30, 2026

Earnings Flash (SNDX) Syndax Pharmaceuticals, Inc. Reports Q1 Revenue $64.9M, vs. FactSet Est of $69.8M - marketscreener.com

Apr 30, 2026
pulisher
Apr 30, 2026

Syndax Pharmaceuticals | 10-Q: Q1 2026 Earnings Report - Moomoo

Apr 30, 2026
pulisher
Apr 30, 2026

Syndax Pharmaceuticals Sees 2026 Total R&D Plus SG&A Expenses Approximately $400 M>SNDX - Moomoo

Apr 30, 2026
pulisher
Apr 30, 2026

Cancer drug sales top $100M as Syndax lines up late-2026 trial data - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

Syndax (NASDAQ: SNDX) triples revenue as Revuforj and Niktimvo ramp - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

Syndax Pharmaceuticals | 8-K: Syndax Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo

Apr 30, 2026
pulisher
Apr 30, 2026

Syndax (NASDAQ: SNDX) posts 224% Q1 revenue surge and lower loss - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

Vanguard Capital Management holds 4.46M shares in Syndax (SNDX) - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

Syndax Pharmaceuticals earnings face test as competition heats up By Investing.com - Investing.com India

Apr 30, 2026
pulisher
Apr 30, 2026

Syndax Pharmaceuticals earnings face test as competition heats up - Investing.com UK

Apr 30, 2026

Syndax Pharmaceuticals Inc (SNDX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$28.32
price down icon 0.14%
$50.44
price up icon 0.48%
$95.50
price down icon 3.88%
$139.44
price down icon 0.41%
$147.21
price down icon 0.47%
ONC ONC
$297.49
price up icon 0.12%
大文字化:     |  ボリューム (24 時間):